Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey

Affiliation auteurs!!!! Error affiliation !!!!
TitreExpectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey
Type de publicationJournal Article
Year of Publication2018
AuteursLorcet M, Lortholary A, Kurtz JEmmanuel, Berton-Rigaud D, Fabbro M, Rouge TDe la Mott, Kaminsky-Forrett MChristine, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Bessard AClaire Har, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, Ray-Coquard I, Lobbedez FJoly
JournalBULLETIN DU CANCER
Volume105
Pagination465-474
Date PublishedMAY
Type of ArticleArticle
ISSN0007-4551
Mots-clésMaintenance, Ovarian cancer, Survey
Résumé

Background > Expression IV survey evaluated the patients' expectations to a maintenance therapy. Methods > From January 2015 to March 2016, 401 French patients, in first line or recurrent disease, answered a 24-items anonymous questionnaire. The results were specifically analyzed according to the demographic characteristics and treatment lines. Results > Among the patients, 62% had already been informed about maintenance therapy. Thirty-seven percent of patients received a maintenance treatment: 111 patients during first line and 39 patients in relapse. Expectations of patients were: 1) the chance of cure (73%), 2) the tumor shrinkage (36%), 3) quality of life improvement (35%) and 4) tumor growth reduction (27%). Among the responders, 42% were willing to take the treatment for 6-24 months, 20% for 24-60 months and 38% until tumor progression. 64% of patients expected more than a 6 months progression-free survival. Patients older than 70 years were less informed than their younger counterparts (48% vs 66%) and had lesser hope for cure with maintenance treatment (60% vs 77%). Patients in relapse had more expectation than patients in remission (tumor shrinkage: 47% vs 22%, slowing of tumor growth: 37% vs 15%, improving the progression-free survival of more than 6 months: 71% vs 53%, respectively). Among patients, 48% in relapse consented to take a treatment until progression vs 24% of patients in remission. Conclusion > This sub-analysis in French patients demonstrate a gap between the efficacy of maintenance therapy and the patients' expectations in ovarian cancer, particularly in relapsing disease justifying better information and explanations.

DOI10.1016/j.bulcan.2018.01.015